MELBOURNE, AUSTRALIA -- (Marketwired) -- 08/30/13 -- Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that it has received its Clinical Laboratory Permit from the New York State Department of Health ("DoH"). In late July, the Company's Melbourne laboratories were inspected under New York's DoH Clinical Laboratory Evaluation Program ("CLEP") and, following the two-day audit, it subsequently received a Laboratory Evaluation Report with "No significant deficiencies". Thus, the permit was able to be issued immediately.
This permit allows the Company to test BREVAGen from residents of New York State -- a densely populated state of nearly 20 million people -- and completes the out of state licensures allowing the Company to provide testing services to all 50 US states. The Company can now meet requests received from New York physicians to provide the BREVAGen test to patients as part of their clinical practice. Phenogen Sciences Inc. (Genetic Technologies' US subsidiary) will be appointing representatives in the near future to cover this state, with a particular emphasis on New York City.
The addition of this important territory will augment the current market adoption, which the Company notes is delivering significant increases in the number of test samples provided to the laboratory during the current quarter to date.
"This is a wonderful endorsement of the quality of our laboratory systems and the validation package provided by our highly qualified staff," said CEO, Ms. Alison Mew. "Importantly, it also allows women across the United States access to BREVAGen to deliver comprehensive breast health care."
About Genetic Technologies Limited
Genetic Technologies is an established diagnostics company with more than 20 years of experience in commercializing genetic testing, non-coding DNA and product patenting. The Company has operations in Australia and the U.S. and is dual-listed on the ASX (Code: GTG) and NASDAQ (Ticker: GENE). Genetic Technologies is focused on the commercialization of its patent portfolio through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics assets. Its U.S. subsidiary, Phenogen Sciences Inc., offers novel predictive testing and assessment tools to help physicians proactively manage women's health. Phenogen's lead product, BREVAGen, is a first in class, clinically validated risk assessment test for non-familial breast cancer.
For more information, please visit http://www.gtglabs.com and http://www.phenogensciences.com
Safe Harbor Statement
Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.
FOR FURTHER INFORMATION PLEASE CONTACT
Ms. Alison J. Mew
Chief Executive Officer
Genetic Technologies Limited
Phone: +61 3 8412 7000
Laura Forman (USA)
Blueprint Life Science Group
+1 (415) 375 3340, Ext. 103
Most Popular Stories
- Obama, Ukraine Discuss Russian Incursion in Crimea
- Chinese May Have Spotted Malaysia Airlines Debris
- Social Media Causee Sleep Deprivation in Students
- First-time Jobless Claims Drop Unexpectedly
- General Electric Plans IPO of Credit Card Unit
- SXSW Crash Kills 2, Injures 23
- U.S. Business Inventories Up, Retail Sales Down
- 'Candy Crush' Maker Files IPO
- Banks Buying Little From Minority Firms: Study
- First-time U.S. Jobless Claims Hit 3-month Low